Bradley Pharmaceuticals layoffs

Share this article:
Nearly two-thirds of Bradley Pharmaceuticals work force is expected to be let go following the company's acquisition by Nycomed.

According to a report in the Star-Ledger, Nycomed, a Swiss specialty drugmaker that has local offices in Florham Park, told New Jersey state officials that it plans to eliminate 196 jobs that were once based at Bradley's headquarters in Fairfield. The layoffs take effect April 30, according to information on the New Jersey Department of Labor's website.

When the $346 million deal was completed last month, Nycomed said it would transfer “key employees” of Bradley from Fairfield to Florham Park, which will be home to the Swiss company's PharmaDerm division. Prior to the sale, Bradley had roughly 300 employees.

An undisclosed number of layoffs were also made on Nycomed's side. The PharmaDerm unit will have 150 to 160 employees, some 30 to 35 of whom will work at Florham Park, the Star-Ledger reported.

The purchase of Bradley makes privately held Nycomed one of the top five companies selling prescription dermatology products.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.